Elevation Oncology (ELEV) Competitors $0.33 +0.02 (+5.49%) As of 04/16/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELEV vs. CABA, INZY, PYRGF, ASRT, UNCY, CNTX, QNCX, JSPR, MGX, and MDCXShould you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Cabaletta Bio (CABA), Inozyme Pharma (INZY), PyroGenesis Canada (PYRGF), Assertio (ASRT), Unicycive Therapeutics (UNCY), Context Therapeutics (CNTX), Quince Therapeutics (QNCX), Jasper Therapeutics (JSPR), Metagenomi (MGX), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry. Elevation Oncology vs. Cabaletta Bio Inozyme Pharma PyroGenesis Canada Assertio Unicycive Therapeutics Context Therapeutics Quince Therapeutics Jasper Therapeutics Metagenomi Medicus Pharma Cabaletta Bio (NASDAQ:CABA) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, community ranking, media sentiment and dividends. Which has higher valuation and earnings, CABA or ELEV? Cabaletta Bio is trading at a lower price-to-earnings ratio than Elevation Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$67.68M-$2.34-0.46Elevation OncologyN/AN/A-$45.70M-$0.81-0.41 Do analysts recommend CABA or ELEV? Cabaletta Bio currently has a consensus price target of $21.00, suggesting a potential upside of 1,844.44%. Elevation Oncology has a consensus price target of $3.39, suggesting a potential upside of 923.80%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Elevation Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Elevation Oncology 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30 Is CABA or ELEV more profitable? Cabaletta Bio's return on equity of -50.10% beat Elevation Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -50.10% -45.49% Elevation Oncology N/A -59.73%-40.05% Does the MarketBeat Community favor CABA or ELEV? Cabaletta Bio received 56 more outperform votes than Elevation Oncology when rated by MarketBeat users. Likewise, 72.52% of users gave Cabaletta Bio an outperform vote while only 66.10% of users gave Elevation Oncology an outperform vote. CompanyUnderperformOutperformCabaletta BioOutperform Votes9572.52% Underperform Votes3627.48% Elevation OncologyOutperform Votes3966.10% Underperform Votes2033.90% Does the media favor CABA or ELEV? In the previous week, Cabaletta Bio's average media sentiment score of 1.89 beat Elevation Oncology's score of 1.87 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Overall Sentiment Cabaletta Bio Very Positive Elevation Oncology Very Positive Which has more risk and volatility, CABA or ELEV? Cabaletta Bio has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Do institutionals and insiders hold more shares of CABA or ELEV? 83.7% of Elevation Oncology shares are owned by institutional investors. 9.9% of Cabaletta Bio shares are owned by company insiders. Comparatively, 8.1% of Elevation Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryCabaletta Bio beats Elevation Oncology on 10 of the 15 factors compared between the two stocks. Remove Ads Get Elevation Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELEV vs. The Competition Export to ExcelMetricElevation OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.58M$2.85B$5.28B$7.35BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-0.4030.3821.6917.68Price / SalesN/A433.55372.8092.89Price / CashN/A168.6838.1534.64Price / Book0.263.416.353.94Net Income-$45.70M-$72.06M$3.20B$247.45M7 Day Performance22.48%4.36%3.92%3.17%1 Month Performance-37.12%-18.95%-10.36%-8.53%1 Year Performance-92.01%-28.83%10.27%0.32% Elevation Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELEVElevation Oncology3.2753 of 5 stars$0.33+5.5%$3.39+923.8%-92.5%$19.58MN/A-0.4040Positive NewsHigh Trading VolumeCABACabaletta Bio2.628 of 5 stars$1.15+3.2%$21.00+1,734.1%-93.4%$58.10MN/A-0.5350Positive NewsINZYInozyme Pharma2.8355 of 5 stars$0.90+10.1%$14.56+1,510.3%-80.2%$58.07MN/A-0.5850News CoveragePYRGFPyroGenesis CanadaN/A$0.30-5.1%N/A-6.0%$56.68M$9.14M-5.0690Gap UpASRTAssertio2.001 of 5 stars$0.59-6.2%$2.75+367.4%-21.9%$56.35M$124.96M-0.8120Analyst UpgradeNews CoveragePositive NewsUNCYUnicycive Therapeutics2.8334 of 5 stars$0.46-10.7%$5.25+1,039.3%-46.8%$55.16M$680,000.00-0.489Gap UpCNTXContext Therapeutics1.4529 of 5 stars$0.61+1.0%$6.17+919.3%-40.7%$54.27MN/A-0.667QNCXQuince Therapeutics2.6229 of 5 stars$1.22-1.6%$8.00+555.7%+0.4%$53.68MN/A-0.9860Gap DownJSPRJasper Therapeutics1.9503 of 5 stars$3.57-6.3%$62.50+1,650.7%-83.8%$53.63MN/A-0.7520Positive NewsMGXMetagenomi1.8851 of 5 stars$1.43+1.4%$13.00+809.1%-82.1%$53.46M$52.30M-0.55236Gap DownMDCXMedicus PharmaN/A$3.84+6.1%$10.00+160.4%N/A$51.51MN/A0.00N/AAnalyst Forecast Remove Ads Related Companies and Tools Related Companies CABA Alternatives INZY Alternatives PYRGF Alternatives ASRT Alternatives UNCY Alternatives CNTX Alternatives QNCX Alternatives JSPR Alternatives MGX Alternatives MDCX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELEV) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELEV Stock Free ELEV Stock Alerts